###begin article-title 0
Upregulation of Mitochondrial Uncoupling Protein-2 by the AMP-Activated Protein Kinase in Endothelial Cells Attenuates Oxidative Stress in Diabetes
###end article-title 0
###begin p 1
###xml 36 58 36 58 <email xmlns:xlink="http://www.w3.org/1999/xlink">ming-hui-zou@ouhsc.edu</email>
Corresponding author: Ming-Hui Zou, ming-hui-zou@ouhsc.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-Recent evidence suggests that the AMP-activated protein kinase (AMPK) is an important therapeutic target for diabetes. The present study was conducted to determine how AMPK activation suppressed tyrosine nitration of prostacyclin synthase in diabetes.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 89 93 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
RESEARCH DESIGN AND METHODS-Confluent human umbilical vein endothelial cells (HUVECs) or mice were treated with 5-amino-4-imidazole carboxamide riboside (AICAR) for the detection of AMPK phosphorylation and the expression of mitochondrial uncoupling protein (UCP)-2.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 85 86 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 237 238 237 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 239 240 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 613 614 613 614 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 615 616 615 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1132 1133 1132 1133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1134 1135 1134 1135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1194 1198 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
RESULTS-Exposure of HUVECs to high glucose (30 mmol/l) increased superoxide anions (O2.-) and prostacyclin synthase nitration. In addition, overexpression of constitutively active AMPK (Ad-CA-AMPK) or the addition of AICAR reduced both O2.- and prostacyclin synthase nitration caused by high glucose, whereas adenoviral overexpression of dominant-negative AMPK mutants (Ad-DN-AMPK) enhanced the latter effects of high glucose. Exposure of HUVECs to either AICAR or metformin caused AMPK-dependent upregulation of both UCP-2 mRNA and UCP-2 protein. Furthermore, overexpression of UCP-2 significantly ablated both O2.- and prostacyclin synthase nitration triggered by high glucose. Furthermore, overexpression of Ad-CA-AMPK increased, whereas overexpression of Ad-DN-AMPK inhibited AICAR-induced phosphorylation of p38 kinase at Thr180/Tyr182. Inhibition of p38 kinase with SB239063, which had no effect on AICAR-induced AMPK-Thr172 phosphorylation, dose dependently suppressed AICAR-induced upregulation of UCP-2, suggesting that AMPK lies upstream of p38 kinase. Finally, AICAR markedly increased UCP-2 expression and reduced both O2.- and prostacyclin synthase nitration in diabetic wild-type mice but not in their AMPKalpha2-deficient counterparts in vivo.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 99 100 99 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
CONCLUSIONS-We conclude that AMPK activation increases UCP-2, resulting in the inhibition of both O2.- and prostacyclin synthase nitration in diabetes.
###end p 6
###begin p 7
Published ahead of print at  on 3 October 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 141 142 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 143 144 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 405 406 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 645 646 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 864 865 849 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 881 882 866 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 883 884 868 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 895 896 880 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 897 898 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 942 944 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 958 960 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 983 985 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1029 1030 1007 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1033 1035 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1036 1038 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1045 1046 1023 1024 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1047 1048 1025 1026 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1050 1052 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1321 1323 1299 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 1559 1561 1537 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 1562 1564 1540 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1590 1592 1568 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 1593 1595 1571 1573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 2015 2017 1993 1995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 2100 2102 2078 2080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 1626 1630 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
AMP-activated protein kinase (AMPK) is a heterotrimer made up of alpha-, beta-, and gamma-subunits, each of which has at least two isoforms (1-3). Increases in the AMP-to-ATP ratio activate AMPK by a number of mechanisms, including direct allosteric activation and alpha-subunit phosphorylation (at Thr172) by at least two AMPK kinases (i.e., LKB1 and calcium calmodulin-dependent kinase kinase [caMKK]) (4). AMPK is ubiquitous and is activated in a variety of cell types by inhibition of ATP production (i.e., anoxia and ischemia) or acceleration of ATP consumption (i.e., muscle contraction and fasting). As first noted by Hardie and Carling (1), AMPK activation appears to be a fundamental component of cellular responses to stresses that threaten cell viability. AMPK is phosphorylated and activated in various tissues by hormones acting through Gq receptors (5), adiponectin (6,7), leptin (8,9), alpha- and beta-adrenoreceptor agonists (10), metformin (11), thiazolidinediones (12), and oxidants, such as peroxynitrite (ONOO-) (13,14) and H2O2 (15). Activation of AMPK leads to the phosphorylation of a number of target molecules, resulting in, among other things, increased fatty acid oxidation and muscle glucose transport (to generate more ATP) and inhibition of various biosynthetic processes (to conserve ATP) (16). Increasing evidence suggests that the functions of AMPK are beyond energy metabolism. For example, both endothelial nitric oxide (NO) synthase (eNOS) and neuronal NO synthase (nNOS) are targets of AMPK in the endothelium and muscle (17,18). Winder and colleagues (19,20) have shown that treatment of rats with 5-amino-4-imidazole carboxamide riboside (AICAR) increases the expression of a wide variety of proteins in muscle, including the GLUT-4 glucose transporter and several mitochondrial oxidative enzymes. AMPK activation has also been shown to increase the expression of mitochondrial uncoupling protein (UCP)-2 in liver after infection with constitutively active AMPK (Ad-CA-AMPK) (21). Similar effects of AMPK on UCP2 and UCP3 have been reported in skeletal muscle (22).
###end p 9
###begin p 10
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 791 792 791 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1321 1322 1321 1322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1408 1410 1408 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
Strong accumulating evidence suggests that oxidative stress, defined as increased formation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and/or decreased antioxidant potentials, plays an important role in the development of diabetic complications (23-27). This hypothesis is supported by the finding that many biochemical pathways strictly associated with hyperglycemia (glucose auto-oxidation, polyol pathway, prostanoid synthesis, and protein glycation) increase the production of free radicals and oxidants (27). The functions of many proteins are likely affected by increased oxidant levels. We have found (24-26) that prostacyclin synthase, an enzyme releasing vasoprotective prostacyclin, is particularly susceptible to tyrosine nitration by RNS, including ONOO-. In cultured endothelial cells, hyperglycemic medium increases the levels of nitrated prostacyclin synthase and decreases prostacyclin synthase activity (20,23). Tyrosine nitration of prostacyclin synthase and consequent thromboxane receptor activation are thought to be important mechanisms contributing to the initiation and progression of vascular complications in diabetes (rev. in 23). This is because of the downregulation of the protective actions of NO and prostacyclin and accumulation of nonmetabolized prostaglandin H2, which promotes platelet aggregation, atheroma accumulation, and thrombus formation (23).
###end p 10
###begin p 11
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 561 562 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 643 644 643 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
Emerging data support a role for ROS and RNS in cell signaling. Lee and Griendling (28) found that angiotensin II augments O2.- production in smooth muscle cells via NADH/NADPH oxidase-like enzymatic activity. This enzymatic system now appears to be involved in a number of "maladaptive" characteristics of atherosclerosis, such as PDGF-induced cell proliferation (29), smooth muscle cell hypertrophy (30), diabetic retinopathy (31), and impaired NO bioactivity (32). Our earlier results had also demonstrated that pathologically relevant concentrations of ONOO- are capable of activating AMPK independently of changes in AMP/ATP and that ONOO--dependent AMPK activation occurs during hypoxia reoxygenation (13) and in metformin-treated endothelial cells (33). However, the consequences of AMPK activation on cellular oxidative stress remain to be determined. In the present study, we provide evidence that AMPK prevents oxidative stress associated with diabetes, in part, by upregulating mitochondrial UCP-2.
###end p 11
###begin title 12
RESEARCH DESIGN AND METHODS
###end title 12
###begin p 13
A full description of the research design and methods, including adenoviral infection, RT-PCR of UCP-2 mRNA, prostacyclin synthase activity assays, NO bioactivity, immunocytochemistry, and high-performance liquid chromatography (HPLC) detection of 3-nitrotyrosine can be found in an online appendix available at .
###end p 13
###begin p 14
###xml 133 136 129 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 138 142 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 182 186 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 298 302 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 366 370 <span type="species:ncbi:10090|species:ncbi:10095">Mice</span>
###xml 492 496 <span type="species:ncbi:10090|species:ncbi:10095">Mice</span>
The animal protocol was reviewed and approved by the institutional animal care and use committee. Male AMPKalpha2 knockout (KO) (AMPK-/-) mice, which had been cross-bred with C57BL6 mice, were bred at the animal house of the University of Oklahoma Health Sciences Center. Their littermates, C57BL6 mice, were obtained from The Jackson Laboratories (Bar Harbor, ME). Mice were housed in temperature-controlled cages with a 12-h light/dark cycle and given free access to water and normal chow. Mice aged 10 weeks were randomly divided into control and treated groups.
###end p 14
###begin p 15
###xml 740 742 736 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 748 750 744 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 14 18 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 43 47 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 168 172 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 298 302 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 627 631 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
AMPKalpha2 KO mice and age-matched C57BL/6 mice were used to study whether AICAR attenuates diabetes-enhanced UCP-2 expression and prostacyclin synthase nitration. The mice were made diabetic after five consecutive injections of 50 mg/kg streptozotocin (STZ) in citrate buffer, pH 4.5. Nondiabetic mice were injected with a comparable volume of citrate buffer. Glucose levels were measured in tail blood by a Free Style blood glucose monitoring system (TheraSense, Alameda, CA). Hyperglycemia was confirmed by nonfasting blood glucose >200 mg/dl (11 mmol/l) 1 week after the initial STZ injection. The nondiabetic and diabetic mice were randomly divided into three groups: control, STZ/untreated, and STZ but treated with AICAR (250 mg . kg-1 . day-1 s.c.). Six weeks later, the animals were killed, and the aorta was collected for analysis.
###end p 15
###begin title 16
Cell culture.
###end title 16
###begin p 17
###xml 614 615 614 615 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 845 847 845 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 214 218 <span type="species:ncbi:9913">calf</span>
Human umbilical vein endothelial cells (HUVECs) (American Type Culture Collection, Rockville, MD) were cultured in endothelial basal media (EBM). When they reached confluence, the cells were maintained in 1% fetal calf serum and exposed to normal glucose (5.5 mmol/l) or high glucose (30 mmol/l) for 3-7 days, during which the medium was changed every 2 days. Control groups (to account for media hyperosmolarity) were exposed to mannitol (24.5 mmol/l) in normal medium containing glucose (5.5 mmol/l). After incubation, the media were collected, and assays were conducted as described below. For measurements of O2.- and cyclic GMP, the growth medium was replaced by PBS containing no glucose. Unless otherwise noted, these measurements were performed on cells or the PBS bathing cells, which were stimulated by the calcium ionophore A23187 (10-5 mol/l, 2 h).
###end p 17
###begin title 18
Adenovirus infection.
###end title 18
###begin p 19
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
HUVECs were infected with adenovirus encoding either Ad-DN-AMPK or Ad-UCP-2, as described previously (13,14,33). Adenoviruses encoding green fluorescent protein (GFP) served as a control.
###end p 19
###begin title 20
Measurement of intracellular ROS.
###end title 20
###begin p 21
###xml 15 16 15 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 257 258 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 259 260 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 437 438 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 439 440 438 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 615 617 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 618 620 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
Intracellular O2.- was measured using the dihydroethidium (DHE) fluorescence/HPLC assay (34) with minor modification. Briefly, HUVECs were incubated with 0.5 mumol/l DHE for 30 min, harvested, and then methanol extracted. Oxyethidium (a product of DHE and O2.-) and ethidium (a product of DHE auto-oxidation) were separated and quantified using a C-18 HPLC column (mobile phase: gradient of acetonitrile and 0.1% trifluoroacetic acid). O2.- production was determined by the conversion of DHE into oxyethidium. ROS production in aorta was assayed using 5 mumol/l lucigenin chemiluminescence as described previously (24-26).
###end p 21
###begin title 22
Statistical analysis.
###end title 22
###begin p 23
###xml 182 183 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical comparison was performed using a one- or two-way ANOVA, and intergroup differences were determined using the Bonferroni inequality. Values are expressed as means +/- SE. P < 0.05 was considered significant.
###end p 23
###begin title 24
RESULTS
###end title 24
###begin p 25
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 143 144 143 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 145 146 145 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 628 629 628 629 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 666 667 666 667 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 704 705 704 705 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 843 844 843 844 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 910 911 910 911 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 912 913 912 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 931 932 931 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 925 932 925 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 994 995 994 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 996 997 996 997 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1047 1048 1047 1048 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1049 1050 1049 1050 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1183 1184 1183 1184 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1185 1186 1185 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1211 1212 1211 1212 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1213 1214 1213 1214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1324 1325 1324 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1318 1325 1318 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
AICAR reduces high glucose-induced oxidative stress in HUVECs. Our earlier studies (24,25) demonstrated that hyperglycemia not only increases O2.- production and tyrosine nitration of prostacyclin synthase but also reduces NO bioactivity, as determined by cyclic GMP levels. A subsequent study (32) revealed that the AMPK activator, metformin, dramatically attenuates the latter effect. To understand whether the beneficial effects of AMPK activation may be attributable to its ability to reduce oxidative stress, we tested the effect of AICAR on markers of oxidative stress in HUVECs. Confluent HUVECs were exposed to 5 mmol/l d-glucose (normal glucose), 30 mmol/l d-glucose (high glucose), or 5 mmol/l d-glucose plus 25 mmol/l mannitol (OG) for 72 h with or without 0.5 mmol/l AICAR. High glucose but not the osmotic control (i.e., 5 mmol/l d-glucose plus 25 mmol/l mannitol) caused a threefold increase of O2.- in HUVECs (Fig. 1A). Administration of 0.5 mmol/l AICAR had no effect on basal O2.- production but attenuated high glucose-enhanced O2.- release. We also examined the effect of AICAR on NO bioactivity, which depends on the overall production and/or depletion of NO by O2.-. In line with elevated O2.- release, high glucose significantly reduced the levels of cyclic GMP, and AICAR prevented this effect (Fig. 1B). Furthermore, AICAR increased the phosphorylation of eNOS-Ser1177, whereas it had no effects on the total amount of eNOS protein in high glucose-exposed HUVECs (data not shown). These results suggest that AICAR might maintain NO bioactivity under high glucose conditions by increasing NO release and/or counteracting oxidative stress.
###end p 25
###begin p 26
###xml 159 160 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 153 160 149 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 503 504 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 664 665 644 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 671 672 651 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 798 799 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 792 799 768 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 1053 1054 1029 1030 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1055 1056 1031 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1064 1065 1040 1041 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
Further analysis of the antioxidant effects of AICAR was performed by measuring 8-iso-prostaglandin F2alpha, a marker of lipid peroxidation. As shown in Fig. 1C, high glucose markedly increased 8-iso-prostaglandin F2alpha levels. Although AICAR had no effect on basal levels of 8-iso-prostaglandin F2alpha, it partially but significantly reduced high glucose-induced increases in 8-iso-prostaglandin F2alpha. AICAR did not completely abolish high glucose-enhanced 8-iso-prostaglandin F2alpha in HUVECs (P < 0.05, normal glucose vs. high glucose plus AICAR). To understand whether AICAR acts as an oxidant scavenger, we exposed HUVECs to chemically synthesized ONOO-. ONOO- significantly increased 8-iso-prostaglandin F2alpha levels; however, cotreatment with AICAR did not alter this effect (Fig. 1C). Additional experiments revealed that AICAR had no effect on the reduction of cytochrome C caused by xanthine/xanthine oxidase (data not shown). Thus, the reduction of oxidative stress by AICAR cannot be attributed to its ability to directly scavenge O2.- or ONOO-.
###end p 26
###begin title 27
AICAR inhibits high glucose-induced nitration and inactivation of prostacyclin synthase.
###end title 27
###begin p 28
###xml 21 23 21 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 187 193 187 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#945;</sub>
###xml 328 329 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 322 329 318 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 431 437 427 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#945;</sub>
###xml 483 489 475 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#945;</sub>
###xml 526 527 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 520 527 508 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>D</italic></xref>
Our earlier studies (24,25) had demonstrated that high glucose increases tyrosine nitration of prostacyclin synthase, which inhibits prostacyclin synthase activity. Analysis of 6-keto-PGF1alpha concentrations revealed that high glucose, but not mannitol, significantly suppressed prostacyclin synthase activity in HUVECs (Fig. 1D). Interestingly, 1 mmol/l AICAR significantly attenuated high glucose-induced reduction of 6-keto-PGF1alpha but had no effect on the levels of 6-keto-PGF1alpha in cells exposed to mannitol (Fig. 1D).
###end p 28
###begin p 29
###xml 253 254 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 247 254 247 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 292 299 292 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
We next determined whether increased prostacyclin synthase activity was due to increased prostacyclin synthase expression. Under normal glucose conditions, 1 mmol/l AICAR (1- to 72-h exposure) altered neither prostacyclin synthase protein levels (Fig. 2A) nor prostacyclin synthase activity (Fig. 2B). These results suggest AICAR had no effect on prostacyclin synthase activity or prostacyclin synthase expression in HUVECs.
###end p 29
###begin p 30
###xml 429 430 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 435 436 435 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 423 436 423 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic> and <italic>D</italic></xref>
Because high glucose exposure increased prostacyclin synthase nitration and inactivation, we next determined whether the protective effects of AICAR on prostacyclin synthase activity were due to the reduction of prostacyclin synthase nitration caused by high glucose. Consistent with the idea that AMPK reduces oxidative stress, 0.5 mmol/l AICAR prevented prostacyclin synthase nitration in HUVECs exposed to high glucose (Fig. 2C and D).
###end p 30
###begin title 31
AMPK activation is required for AICAR-induced reduction of oxidative stress.
###end title 31
###begin p 32
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 125 132 125 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 236 243 236 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 268 275 268 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 658 659 658 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 652 659 652 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 767 768 767 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 761 768 761 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
Incubation of HUVECs with AICAR resulted in time-dependent AMPK activation, as determined by Thr172 phosphorylation of AMPK (Fig. 3A). Similarly, a 24-h incubation with 1 mmol/l metformin markedly increased Thr172-AMPK phosphorylation (Fig. 3A). Because either AICAR (Fig. 1A) or metformin (data not shown) significantly reduced ROS production under high glucose conditions, we tested whether AMPK activation was required for this antioxidant effect. Under normal glucose conditions, inhibition of AMPK by adenoviral overexpression of dominant-negative AMPK (Ad-DN-AMPK) significantly increased ROS in HUVECs, whereas GFP overexpression had no effect (Fig. 3B). Moreover, Ad-DN-AMPK overexpression significantly accentuated high glucose-induced ROS production (Fig. 3B). These results suggest that AMPK functions as an endogenous protector against ROS in endothelial cells.
###end p 32
###begin title 33
AMPK attenuates high glucose-induced oxidative stress and prostacyclin synthase nitration through upregulation of UCP-2.
###end title 33
###begin p 34
###xml 236 237 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 230 237 230 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 324 325 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 318 325 318 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 363 364 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 357 364 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 562 563 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 556 563 556 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>D</italic></xref>
To further investigate the mechanism by which AMPK activation reduces oxidative stress, we analyzed UCP-2 expression in HUVECs. Under normal conditions, UCP-2 mRNA was abundant, but very low levels of UCP-2 protein were detected (Fig. 3C). However, exposure of HUVECs to AICAR significantly increased both UCP-2 mRNA (Fig. 3C) and UCP-2 protein expression (Fig. 3D). Importantly, inhibition of AMPK with Ad-DN-AMPK, but not control Ad-GFP, significantly attenuated AICAR-induced UCP-2 expression, implying that AMPK upregulates UCP-2 expression in HUVECs (Fig. 3D).
###end p 34
###begin p 35
###xml 191 192 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 185 192 185 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 310 311 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 304 311 304 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 340 341 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 334 341 334 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 535 536 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 529 536 529 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 584 585 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 578 585 578 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>E</italic></xref>
Next, we tested whether adenoviral overexpression of UCP-2 in HUVECs altered high glucose-induced ROS production. Overexpression of Ad-UCP-2 markedly increased UCP-2 protein in HUVECs (Fig. 4A). In addition, adenoviral overexpression of UCP-2 significantly reduced high glucose-induced increases in ROS (Fig. 4B) and 3-nitrotyrosine (Fig. 4C), with GFP overexpression having no effect on either parameter. Consistent with this result, UCP-2 overexpression markedly inhibited high glucose-induced prostacyclin synthase nitration (Fig. 4D) and prostacyclin synthase inactivation (Fig. 4E).
###end p 35
###begin title 36
Activation of p38 kinase is required for AMPK-dependent UCP-2 expression.
###end title 36
###begin p 37
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 243 250 243 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 691 692 691 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 685 692 685 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 807 808 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 801 808 801 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
The fact that both AMPK and p38 kinase are activated by extracellular stresses (e.g., hypoxia/reoxygenation and osmotic stress) (34,35) prompted us to investigate whether p38 kinase is required for AMPK-dependent UCP-2 expression. As shown in Fig. 5A, the phosphorylation of p38 kinase at Thr180/Tyr182 was markedly increased for up to 4 h after AICAR treatment. In parallel, AICAR increased the phosphorylation of c-Jun, a downstream enzyme of p38 kinase. Adenoviral overexpression of constitutively active AMPK for 24 h before AICAR treatment (2 mmol/l for 2 h) resulted in an increase in c-Jun and p38 kinase phosphorylation that was even greater than that elicited by AICAR alone (Fig. 5B). Conversely, overexpression of Ad-DN-AMPK inhibited AICAR-induced phosphorylation of p38 kinase and c-Jun (Fig. 5B).
###end p 37
###begin p 38
###xml 246 247 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 240 247 240 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 379 386 379 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 507 508 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 501 508 500 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>E</italic></xref>
To determine whether p38 kinase is required for AMPK-dependent UCP-2 expression, we treated HUVECs with SB239063, a potent p38 kinase inhibitor. Incubation of HUVECs with SB239063 abolished AICAR-induced phosphorylation of both p38 kinase (Fig. 5C) and c-Jun (data not shown). Importantly, SB239063 also suppressed AICAR-induced upregulation of UCP-2 in a dose-dependent manner (Fig. 5D). When used at concentrations up to 20 mumol/l, SB239063 did not alter AICAR-induced AMPK-Thr172 phosphorylation (Fig. 5E), suggesting that AMPK lies upstream of p38 kinase.
###end p 38
###begin title 39
Chronic stimulation of AMPK with AICAR attenuates diabetes-induced oxidative stress and prostacyclin synthase nitration.
###end title 39
###begin p 40
###xml 440 441 436 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 669 670 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 680 681 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 736 737 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 747 748 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 873 874 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 883 884 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 939 940 911 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 949 950 921 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1038 1039 1006 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1048 1049 1016 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1432 1433 1376 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1443 1444 1387 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 183 187 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 205 209 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 525 529 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1275 1279 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
To extend our in vitro findings, we investigated the effect of AICAR on prostacyclin synthase nitration and UCP-2 expression associated with STZ-induced diabetes. Ten-week-old C57BL6 mice or AMPKalpha2 KO mice were subjected to five consecutive injections of 50 mg/kg STZ in citrate buffer, pH 4.5, or an equivalent volume of citrate buffer. Two weeks after STZ injection, animals received daily subcutaneous injections of 250 mg/kg AICAR (n = 7) or a corresponding volume of 0.9% NaCl for 6 weeks. One week after injection, mice administered STZ had significantly higher serum glucose levels than their control counterparts (wild type, 488 +/- 25 vs. 119 +/- 7 mg/dl, P < 0.001, n = 11; AMPKalpha2 KO, 493 +/- 27 vs. 129 +/- 11 mg/dl, P < 0.001, n = 9). In addition, diabetic animals had significantly lower body weights (wild type, 16.0 +/- 0.8 vs. 18.8 +/- 1 g, -14.9%, P < 0.05, n = 11; AMPKalpha2 KO, 15.8 +/- 0.9 vs. 17.9 +/- 0.7 g, P < 0.05, n = 10) and plasma insulin concentrations (wild type, 0.3 +/- 0.1 vs. 1.2 +/- 0.2 ng/ml, P < 0.01, n = 11; AMPKalpha2 KO, 0.4 +/- 0.2 vs. 1.0 +/- 0.2 ng/ml) than controls. Diabetic and nondiabetic animals had a similar heart weight (wild type, 70 +/- 3.5 vs. 75 +/- 2.6 mg). Comparison of AICAR and non-AICAR-treated diabetic mice revealed that both groups had similar blood glucose levels (wild type, 488 +/- 25 vs. 461 +/- 28 mg/dl; AMPKalpha2 KO, 493 +/- 27 vs. 509 +/- 27 mg/dl, P < 0.001, n = 9), water consumption (16.1 +/- 0.7 vs. 15.1 +/- 0.5 ml/day), and body weight (17.5 +/- 0.8 vs. 19.1 +/- 0.1 g).
###end p 40
###begin p 41
###xml 41 42 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 236 237 228 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 238 239 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 345 346 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 347 348 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 339 348 331 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic>&#8211;<italic>C</italic></xref>
###xml 444 445 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 446 447 438 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 462 463 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 456 463 448 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 515 516 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 509 516 501 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 571 572 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 565 572 557 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 575 576 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 585 586 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 627 628 619 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 629 630 621 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 752 753 740 741 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 754 755 742 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 865 866 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 875 876 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1047 1048 1031 1032 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1049 1050 1033 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 155 159 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 178 182 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 389 393 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 415 419 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 691 695 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 859 863 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 939 943 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Next, isolated aortas were analyzed for O2.- levels, prostacyclin synthase nitration, and UCP-2 expression. A comparison of aortas from nondiabetic C57BL6 mice and AMPKalpha2 KO mice revealed that AMPKalpha2 KO aortas exhibited higher O2.- levels and prostacyclin synthase nitration but had lower levels of prostacyclin synthase activity (Fig. 6A-C). Compared with aortas from nondiabetic mice, those from diabetic mice had markedly increased O2.- levels (Fig. 6A), increased prostacyclin synthase nitration (Fig. 6C), and decreased prostacyclin synthase activity (Fig. 6C) (P < 0.01, n = 7). STZ injection exacerbated aortic O2.- levels and prostacyclin synthase nitration in AMPKalpha2 KO mice. Activation of AMPK with AICAR significantly inhibited O2.- release, prostacyclin synthase nitration, and prostacyclin synthase inactivation in diabetic wild-type mice (P < 0.01, n = 7), but AICAR administration had no effect in AMPKalpha2 KO mice. Taken together, these results suggest that AMPK activation is required for the suppression of aortic O2.- formation and prostacyclin synthase nitration by AICAR in vivo.
###end p 41
###begin p 42
###xml 389 390 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 383 390 379 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 526 527 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 520 527 512 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 639 640 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 633 640 621 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 213 217 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 280 284 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 442 446 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 601 605 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 761 765 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 801 805 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Finally, to test whether UCP-2 participates in AMPK-dependent reduction in oxidative stress associated with diabetes, we performed immunohistochemical staining for UCP-2 in aortas from wild-type and AMPKalpha2 KO mice. UCP-2 staining was very weak in aortic tissue from wild-type mice, but was greatly increased by STZ injection, suggesting that diabetes increases UCP-2 expression (Fig. 6D). Similar to the aortas from nondiabetic wild-type mice, nondiabetic AMPKalpha2 KO aortas had barely detectable levels of UCP-2 (Fig. 6D). However, UCP-2 expression was still barely detectable in AMPKalpha2 KO mice with STZ-induced diabetes (Fig. 6D). In accord with these results, AICAR significantly increased UCP-2 staining in both nondiabetic and diabetic wild-type mice but had no effect in AMPKalpha2 KO mice, suggesting that AMPK is required for UCP-2 expression in vivo.
###end p 42
###begin p 43
###xml 323 329 323 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7</xref>
Administration of catalase does not alter UCP-2 expression enhanced by high glucose. Because several cellular types exhibited reduced AMPK activity in the presence of high glucose and high glucose increases ROS production, we next determined whether the addition of catalase altered UCP-2 expression in HUVECs. As shown in Fig. 7, short exposure (2 h) of HUVECs to high glucose significantly increased the phosphorylation of AMPK Thr172 along with increased detection of UCP-2 in HUVECs. Administration of catalase altered neither AMPK phosphorylation nor UCP-2 expression in HUVECs exposed to high glucose.
###end p 43
###begin title 44
DISCUSSION
###end title 44
###begin p 45
###xml 97 98 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 268 269 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 270 271 270 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 484 485 484 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 486 487 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 602 603 602 603 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 604 605 604 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 210 214 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 714 718 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 744 748 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
In the present study, we have found that AICAR, an activator of AMPK, reduces oxidative stress (O2.- and 3-nitrotyrosine) and increases UCP-2 expression in cultured endothelial cells and in aorta from diabetic mice. In high glucose-exposed HUVECs, AMPK inhibition of O2.- formation and prostacyclin synthase nitration was accompanied by increased NO bioactivity. These protective effects of AMPK were confirmed by the finding that AMPK gene deletion not only exacerbated STZ-induced O2.- production and prostacyclin synthase nitration but also rendered AICAR incapable of protecting against increased O2.- and prostacyclin synthase nitration. The ability of AICAR to upregulate UCP-2 expression in diabetic C57BL6 mice but not in AMPKalpha2 KO mice suggests that AMPK-dependent UCP-2 expression is essential for reduction of oxidative stress by AMPK.
###end p 45
###begin p 46
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 656 661 656 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob/ob</italic>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 864 867 864 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 874 876 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 904 907 904 907 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 917 919 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 1087 1089 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 1090 1092 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 1093 1095 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 1112 1114 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 1229 1231 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 1771 1772 1767 1768 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1773 1774 1769 1770 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2123 2124 2119 2120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2125 2126 2121 2122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2570 2572 2558 2560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 2573 2575 2561 2563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 2789 2791 2777 2779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 2792 2794 2780 2782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 2857 2859 2845 2847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 2860 2862 2848 2850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 662 666 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 719 723 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 868 872 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 908 912 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1299 1304 <span type="species:ncbi:9606">human</span>
###xml 2191 2195 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 2430 2434 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
UCPs are mitochondrial transporters that are present in the inner mitochondrial membrane and belong to a family of mitochondrial anion carriers, which includes adenine nucleotide transporters (36,37). Mild uncoupling of respiration is known to diminish mitochondrial ROS formation by complex I and II (37). Recent evidence implies that the basic role of all UCPs is to prevent oxidative tissue injury by reducing oxidative stress (37). A role for UCP-2 in the downregulation of mitochondrial ROS production is plausible, because available evidence suggests that this protein is expressed in numerous mammalian tissues (37). Macrophages of leptin-deficient ob/ob mice have low UCP-2 levels compared with those of normal mice, and these low UCP-2 levels are associated with increased mitochondrial ROS production (38). In addition, ROS levels in macrophages of UCP-2-/- mice (39) and muscle tissue of UCP-3-/- mice (40,41) exceed wild-type levels. UCP-2 has the ability to reduce ROS not only in mitochondria, but also within the remainder of the cell and even in the extracellular space (36,41,42). Duval et al. (44) have recently shown that UCP-2-mediated uncoupling in endothelial cells decreases extracellular ROS. Lee et al. (45) have demonstrated that adenoviral transfer of the UCP-2 gene into human airway epithelial cells profoundly suppresses ROS generation, decreases NF-kappaB activity, enhances eNOS transcription, and improves endothelium-dependent vascular relaxation. Nevertheless, the molecular mechanisms underlying UCP-2 expression remain poorly defined. We have provided the first evidence that AMPK is essential for UCP-2 expression in endothelial cells in vivo. In line with this hypothesis, we have found that activation of AMPK with AICAR prevents O2.- formation, NO inactivation, and prostacyclin synthase nitration that accompanies prolonged exposure of HUVECs to high glucose. Also in line with this hypothesis, pharmacological or genetic inhibition of AMPK abolished the ability of AICAR to not only reduce oxidative stress but also to upregulate UCP-2 expression. The finding that STZ amplified O2.- production and prostacyclin synthase nitration in AMPKalpha2 KO mice strongly suggests that AMPK suppresses oxidative stress. However, the most conclusive evidence for this idea is provided by the finding that AICAR failed to alter markers of oxidative stress or UCP-2 expression in the AMPK-alpha 2 KO mice. Consistent with our results, AMPK activation has also been shown to increase the expression of UCP-2 in liver and in skeletal muscle (21,22). In pre-diabetic (impaired glucose tolerance) subjects, a 1-year lifestyle diabetes prevention program involving increased physiological exercise improves metabolic control and increases UCP-3 levels by twofold (45,46). Physiological exercise is known to lead to AMPK activation (47,48). Activation of AMPK leads to a reduction of oxidative stress and vascular function.
###end p 46
###begin p 47
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 77 78 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 79 80 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 308 309 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 302 309 298 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 349 350 345 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 351 352 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 518 519 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 512 519 504 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 683 685 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 686 688 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r50">50</xref>
###xml 706 707 698 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 708 709 700 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 296 300 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 431 435 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 506 510 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
AMPK is activated by multiple stimuli, including oxidants such as ONOO- and H2O2. Thus, the production of oxidants might be required for AMPK-dependent UCP-2 expression. This idea is supported by the fact that UCP-2 was weakly expressed in endothelial cells from both wild-type and AMPKalpha2 KO mice (Fig. 6D). The ability of STZ to induce aortic O2.- formation, prostacyclin synthase nitration, and UCP-2 expression in wild-type mice, taken with its inability to induce UCP-2 expression in AMPKalpha2 KO mice (Fig. 6D), strongly suggests that intracellular ROS activates AMPK, which then stimulates transcription of the UCP-2 gene. Consistent with this hypothesis, recent studies (49,50) suggested that O2.- itself activates UCP-2 within the matrix by an unspecified mechanism. We propose that ROS-activated AMPK, in return, limits ROS production by increasing mitochondrial UCP-2 expression. That is, AMPK-dependent UCP-2 upregulation is a compensatory mechanism aimed at counteracting intracellular oxidative stress. Collectively, our findings suggest that AMPK is a physiological regulator of ROS that protects endothelial cells against the adverse effects of hyperglycemia by inhibiting the processes that generate oxidants.
###end p 47
###begin title 48
Supplementary Material
###end title 48
###begin title 49
Online-Only Appendix
###end title 49
###begin p 50
M.-H.Z. has received National Institutes of Health Grants HL079584, HL080499, HL074399, and HL089920; a research award from the American Diabetes Association; a research award from the Juvenile Diabetes Research Foundation; a grant from the Oklahoma Center for the Advancement of Science and Technology; and Paul H. Doris Eaton Travis Chair Funds in Endocrinology of the University of Oklahoma Health Sciences Center.
###end p 50
###begin p 51
Parts of this study were presented at the 66th Scientific Session of the American Diabetes Association, Washington, DC, 9-13 June 2006.
###end p 51
###begin title 52
REFERENCES
###end title 52
###begin p 53
###xml 173 174 173 174 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 199 200 199 200 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 227 228 227 228 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 332 333 332 333 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 337 338 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 370 371 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 383 389 383 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
###xml 445 446 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 522 523 487 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 537 543 502 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#945;</sub>
###xml 546 547 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 563 564 524 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 572 573 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 630 631 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
AMPK activation with 0.5 mmol/l AICAR reduces high glucose-induced oxidative stress and prostacyclin synthase nitration in HUVECs. Confluent HUVECs were exposed to 5 mmol/l d-glucose (NG), 30 mmol/l d-glucose (HG), or 5 mmol/l d-glucose plus 25 mmol/l mannitol (OG) for 72 h with or without 0.5 mmol/l AICAR. After the incubation, O2.- (A), cyclic GMP (NO bioactivity) (B), 8-iso-PGF2alpha (blacksquare, square, filled, -AICAR; square, +AICAR) (C), and prostacyclin synthase activity (as reflected by the conversion of PGH2 to 6-keto-PGF1alpha) (D) were assayed (n = 12, #P < 0.01 high glucose vs. normal glucose, club suit symbolP < 0.01 high glucose vs. high glucose plus AICAR. IP, immunoprecipitation; PGIS, prostacyclin synthase; WB, Western blot).
###end p 53
###begin p 54
###xml 301 328 301 328 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 404 405 404 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 411 412 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 486 487 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 546 547 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 552 553 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 652 653 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 660 661 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 718 719 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Chronic administration of AICAR attenuates high glucose-enhanced prostacyclin synthase nitration in HUVECs. Confluent HUVECs were exposed to 0.5 mmol/l AICAR for the indicated time. Prostacyclin synthase, nitrated prostacyclin synthase, and prostacyclin synthase activity were assayed as described in research design and methods. A: Effect of AICAR on prostacyclin synthase protein expression in HUVECs; n = 7. B: Effect of 0.5 mmol/l AICAR on prostacyclin synthase activity in HUVECs; n = 7. square, Control; blacksquare, square, filled, AICAR. C and D: AICAR administration attenuates high glucose-enhanced prostacyclin synthase nitration in HUVECs; n = 5, #P < 0.01 high glucose vs. normal glucose, club suit symbolP < 0.01 high glucose vs. high glucose plus AICAR. IP, immunoprecipitation; PGIS, prostacyclin synthase; WB, Western blot.
###end p 54
###begin p 55
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 212 213 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 260 261 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 341 342 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 427 428 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 473 474 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 544 545 512 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 590 591 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 613 614 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 655 656 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 709 710 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 717 718 670 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 760 761 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
AICAR-induced UCP-2 expression in HUVECS is AMPK dependent. A: AMPK activation by AICAR or metformin. The blot is a representative blot of four blots from four individual experiments. B: Effect of Ad-DN-AMPK on O2.- production induced by high glucose (n = 3, #P < 0.05 normal glucose vs. high glucose or high glucose/Ad-GFP, club suit symbolP < 0.05 Ad-GFP/high glucose/AICAR vs. GFP/high glucose or high glucose, double daggerP < 0.05 Ad-DN-AMPK vs. normal glucose, daggerP < 0.05 AD-DN-AMPK/AICAR/high glucose vs. Ad-GFP/high glucose/AICAR). C: Increase of UCP-2 mRNA by AICAR in HUVECs (n = 3, club suit symbolP < 0.05 control vs. metformin or AICAR). D: AICAR-enhanced UCP-2 expression is AMPK dependent (n = 3, *P < 0.05 vs. GFP vs. GFP plus AICAR, daggerP < 0.05 AICAR plus GFP vs. AICAR plus AD-DN-AMPK).
###end p 55
###begin p 56
###xml 69 70 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 210 211 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 270 271 270 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 286 287 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 294 295 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 370 371 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 421 422 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 498 499 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 506 507 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 582 583 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 643 644 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 745 746 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 753 754 723 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 852 853 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 908 909 858 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 959 960 909 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1053 1054 1003 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1061 1062 1011 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1139 1140 1074 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
UCP-2 overexpression suppresses high glucose-induced ROS generation. A: Overexpression of UCP-2 increases UCP-2 protein in HUVECs. The blot is a representative of three blots from three individual experiments. B: Overexpression of UCP-2 suppresses high glucose-induced O2.- production (n = 3, #P < 0.05 GFP plus high glucose vs. GFP plus normal glucose, club suit symbolP < 0.05 GFP/high glucose vs. UCP-2/high glucose). C: Overexpression of UCP-2 suppresses high glucose-enhanced 3-nitrotyrosine (n = 5, #P < 0.05 GFP plus high glucose vs. GFP plus normal glucose, club suit symbolP < 0.05 GFP plus high glucose vs. UCP-2 plus high glucose). D: Overexpression of UCP-2 attenuates high glucose-induced prostacyclin synthase nitration in HUVECs (n = 5, #P < 0.05 high glucose vs. normal glucose, GFP/high glucose vs. GFP/normal glucose; club suit symbolP < 0.05 GFP/high glucose vs. high glucose or OG; daggerP < 0.05 high glucose/GFP vs. high glucose/UCP-2). E: Effect of UCP-2 overexpression on high glucose-induced prostacyclin synthase inactivation (n = 5, #P < 0.05 normal glucose vs. high glucose or high glucose/GFP, club suit symbolP < 0.05 GFP/high glucose vs. high glucose/UCP-2).
###end p 56
###begin p 57
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 290 291 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 500 501 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 712 713 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 720 721 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 764 765 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 805 806 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 874 875 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 882 883 867 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 926 927 896 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 967 968 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1047 1048 1017 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1055 1056 1025 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1099 1100 1054 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
p38 kinase is required for AMPK-dependent UCP-2 expression. A: Effects of AICAR on the phosphorylation of c-Jun and p38 kinase in HUVECs. Confluent HUVECs were treated with 0.5 mmol/l AICAR at times indicated. The blot is a representative of three blots from three independent experiments. B: AICAR-increased phosphorylation of c-Jun and p38 is AMPK dependent. HUVECs were infected with either Ad-AMPK-CA or AD-AMPK-DN. The blot is a representative of three blots from three independent experiments. C: Effects of SB239063 on AICAR-enhanced phosphorylation of p38 in HUVECs. HUVECs were treated with 0.5 mmol/l AICAR in the presence or absence of different concentrations of SB239063, a selective p38 inhibitor (n = 4, #P < 0.05 AICAR vs. control, club suit symbolP < 0.05 AICAR vs. AICAR plus SB239063). D: Effects of SB239063 on upregulation of UCP-2 expression by AICAR (n = 4, #P < 0.05 AICAR vs. control, club suit symbolP < 0.05 AICAR vs. AICAR plus SB239063). E: Effect of SB239063 on AMPK-Thr172 phosphorylation caused by AICAR in HUVECs (n = 4, #P < 0.05 AICAR vs. control, club suit symbolP < 0.05 AICAR vs. AICAR plus SB239063).
###end p 57
###begin p 58
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 153 154 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 155 156 155 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 227 228 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 237 238 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 279 280 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 318 319 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 402 403 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 452 453 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 576 577 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 586 587 542 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 628 629 569 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 674 675 603 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 750 751 675 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 841 842 766 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 851 852 776 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 893 894 803 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 945 946 850 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1025 1026 910 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1080 1081 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1188 1191 1065 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 1244 1250 1121 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 1253 1254 1130 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1263 1264 1140 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1305 1306 1167 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1357 1358 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 195 199 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 544 548 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 804 808 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1182 1186 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
AMPK reduces oxidative stress, prostacyclin synthase nitration, and UCP-2 expression associated with STZ-induced diabetes. A: Effect of AICAR on aortic O2.- levels in wild-type and AMPKalpha2 KO mice with and without diabetes (n = 6-8, #P < 0.05 STZ vs. control; club suit symbolP < 0.05 STZ plus AICAR vs. STZ, daggerP < 0.05 STZ plus AICAR in AMPKalpha2 KO vs. wild type STZ plus AICAR; double daggerP < 0.05, AMPK KO control vs. wild-type control). B: Effect of AICAR on aortic prostacyclin synthase activity in wild-type and AMPKalpha 2 KO mice with and without diabetes (n = 6-8, #P < 0.05 STZ vs. control, club suit symbolP < 0.05 STZ plus AICAR vs. STZ, double daggerP < 0.05, STZ plus AICAR in wild type vs. STZ plus AICAR in AMPKalpha2 KO). C: Aortic prostacyclin synthase nitration in diabetic mice treated with and without AICAR (n = 6-8, #P < 0.05 STZ vs. control, club suit symbolP < 0.05 STZ plus AICAR vs. STZ in wild type, daggerP < 0.05 STZ plus AICAR in AMPKalpha2 KO vs. STZ in AMPKalpha2 KO, double daggerP < 0.05 wild-type control vs. AMPKalpha2 KO control). D: Immunohistochemical staining of UCP-2 levels in AICAR-treated diabetic wild-type and AMPKalpha2 KO mice (top); AMPK-dependent UCP-2 expression by AICAR in vivo (bottom) (n = 6-8, #P < 0.05 STZ vs. control, club suit symbolP < 0.05 STZ plus AICAR vs. STZ in wild type, daggerP < 0.05 STZ plus AICAR in AMPKalpha2 KO vs. STZ in AMPKalpha2 KO). (Please see  for a high-quality digital representation of this figure.)
###end p 58
###begin p 59
###xml 300 301 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 325 326 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 403 404 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Effects of catalase on high glucose-enhanced expression of UCP-2 in HUVECs. Confluent HUVECs were exposed to high glucose or normal glucose in the presence or absence of 500 units/ml catalase for 2 h. The levels of AMPK-Thr172 and UCP-2 were examined in Western blots by using the specific antibody (n = 3-5, club suit symbolP < 0.05 normal glucose vs. high glucose or high glucose plus catalase, daggerP < 0.05 high glucose vs. high glucose plus catalase). square, P-AMPK. blacksquare, square, filled, UCP2.
###end p 59

